Compare BROS & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BROS | TWST |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 9.2B |
| IPO Year | 2021 | 2018 |
| Metric | BROS | TWST |
|---|---|---|
| Price | $41.66 | $137.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 13 |
| Target Price | $70.72 | ★ $163.67 |
| AVG Volume (30 Days) | ★ 3.8M | 2.7M |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.24 | 63.89 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,638,159,000.00 | $376,572,000.00 |
| Revenue This Year | $30.12 | $21.17 |
| Revenue Next Year | $24.71 | $20.24 |
| P/E Ratio | $102.05 | ★ N/A |
| Revenue Growth | ★ 27.88 | 20.32 |
| 52 Week Low | $36.51 | $23.30 |
| 52 Week High | $74.02 | $219.71 |
| Indicator | BROS | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 42.82 |
| Support Level | $36.96 | $122.05 |
| Resistance Level | $59.07 | $155.44 |
| Average True Range (ATR) | 1.63 | 16.12 |
| MACD | 0.77 | -3.80 |
| Stochastic Oscillator | 68.00 | 7.71 |
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies, and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company-operated shops.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.